WHO approves AstraZeneca COVID vaccine for emergency use
The World Health Organization (WHO) on Monday listed AstraZeneca and Oxford University’s COVID-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world
“We continue to call for COVID19 vaccine developers to submit their dossiers to WHO for review at the same time as they submit them to regulators in high-income countries,” he said.
A WHO statement said it had approved the vaccine as produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.
“In the first half of 2021, it is hoped that more than 300 million doses of the vaccine will be made available to 145 countries through COVAX, pending supply and operational challenges”, the British drugmaker said in a separate statement announcing the approval.
The listing by the UN health agency comes days after a WHO panel provided interim recommendations on the vaccine, saying two doses with an interval of around 8 to 12 weeks should be given to all adults, and can be used in countries with the South African variant of the coronavirus as well.
The WHO’s review found that the Astrazeneca vaccine met the “must-have” criteria for safety, and its efficacy benefits outweighed its risks.
COVAX sharing programme
The AstraZeneca/Oxford shot has been hailed because it is cheaper and easier to distribute than some rivals, including Pfizer/BioNTech’s, which was listed for emergency use by the WHO late in December.
Nearly 109 million people have been reported to be infected by the novel coronavirus globally and more than 2.5 million have died, according to a Reuters tally. Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.
AstraZeneca’s vaccine makes up the lion’s share of doses in the COVAX coronavirus vaccine sharing initiative, with more than 330 million doses of the shot due to begin being rolled out to poorer countries from the end of February.
The WHO established its emergency use listing (EUL) process to help poorer countries without their own regulatory resources quickly approve medicines new diseases like COVID-19, which otherwise could lead to delays.
The COVAX Facility, which is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations and the U.N. Children’s Fund, has said doses would cover an average of 3.3% of total populations of 145 participating countries.